MetaCap

Acurx Pharmaceuticals (ACXP) vs Tempest Therapeutics (TPST)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Acurx Pharmaceuticals is the larger company by market cap ($6.3 million vs $5.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ACXP-20.00%TPST-63.74%
+3%-32%-67%
Oct 7, 20261 yearNov 20, 2026
ACXP-18.11%TPST-62.24%
+3%-31%-65%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ACXP versus TPST key metrics
MetricACXPTPST
Share price$1.04$0.287
Market cap$6.30M$5.74M
1-day change+0.97%-6.18%
YTD return—-90.00%
1-year return—-91.80%
5-year return—-99.77%
EPS (TTM)$-1.90$-3.16
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-7.97M$-26.26M
52-week high$7.54$4.22
52-week low$0.90$0.28
Distance from 52-week high-86.21%-93.20%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+1534.62%+2339.02%
Average volume97.29K2.56M
Shares outstanding6.06M20.00M
Employees44
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Acurx Pharmaceuticals

ACXP stock →

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

About Tempest Therapeutics

TPST stock →

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

ACXP vs TPST FAQ

Which is bigger, Acurx Pharmaceuticals or Tempest Therapeutics?

Acurx Pharmaceuticals (ACXP) is larger, with a market capitalization of $6.30M compared with $5.74M for Tempest Therapeutics (TPST).

Are Acurx Pharmaceuticals and Tempest Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons